Ingenium Pharmaceuticals AG has expanded its current strategic alliance with Elan Corporation plc to increase the use of specific Ingenium technologies outside of the original research focus area of pain management. Under the terms of the agreement, Ingenium will produce specific mouse models critical for drug target validation using its INGENOtyping platform.

These models are in addition to those already in development for the original partnership announced in March 2003 and will be used in other Elan areas of research. Financial terms of the new agreement were not disclosed.

"In the short time since March, we have seen the value of Ingenium's discovery technology platforms and the INGENOtyping approach for rapidly generating genetically altered models," said Elan's Global Head of Research Stephen B. Freedman. "We are excited about the speed by which crucial models already were being developed for our pain research collaboration with Ingenium. The development of these models represent the first achievements in our collaboration and demonstrate the advantages of INGENOtyping which we will now access for other key areas of drug discovery and development."

"Our research relationship with Elan has been extremely positive and the synergy between our Deductive Genomics technology and Elan's expertise in drug discovery and development is very powerful," said Michael C. Nehls, Chief Executive Officer of Ingenium. "We are pleased that Elan has chosen to increase their interaction with us which we see as a further validation of our successful collaboration."